La Jolla Pharma +22.4% AH. Wedbush starts at Outperform.

Wedbush's Liana Moussatos has started coverage on La Jolla Pharma (LJPC) with an Outperform and $27 PT.

Moussatos sees a "70% probability of a positive outcome" for a Phase 2a trial of La Jolla's GCS-100 drug in March, and thinks the drug could see peak annual sales of $1B.

From other sites
Comments (4)
  • millsy1
    , contributor
    Comments (164) | Send Message
    Still need phase 2 results but nice to see some coverage by wedbush and noble(both have buy ratings)
    25 Feb 2014, 06:04 PM Reply Like
  • cksinvestments
    , contributor
    Comments (11) | Send Message
    Wonderful, thank you Liana.
    25 Feb 2014, 07:45 PM Reply Like
  • Stealthe
    , contributor
    Comments (88) | Send Message
    Baker Brothers must might smiling right now.... 10% stake
    25 Feb 2014, 10:10 PM Reply Like
  • Patent News
    , contributor
    Comments (1475) | Send Message
    what price did baker brothers get in?
    28 Feb 2014, 03:16 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs